Value through Innovation17 January 2013

Your search results.

  1. Barofold

    • Size: 4 kB
    • Last Update: 12.11.2012
  2. Research and development in Practice: Lung Cancer (NSCLC)

    Dr Mehdi Shahidi, Associate Therapeutic Area Head, Oncology, Boehringer Ingelheim

    • Size: 924 kB
    • Last Update: 8.11.2012
  3. R&D conference poster, 2012

    • Size: 15 kB
    • Last Update: 9.11.2012
  4. Christian Boehringer

    • Size: 37 kB
    • Last Update: 30.11.2012
  5. Christian Boehringer

    • Size: 10 kB
    • Last Update: 30.11.2012
  6. IIS-Abbreviated Study Outline 2012-11-23.doc

    1.54 An individual who both initiates and conducts, alone or with others, a clinical trial, and under whose immediate direction the investigational product is administered to, dispensed to, or used by a subject. The term does not include any person other than an individual (e.g.

    • Size: 60 kB
    • Last Update: 30.11.2012
  7. IIS-Study Outline 2012-09-17

    1.54 An individual who both initiates and conducts, alone or with others, a clinical trial, and under whose immediate direction the investigational product is administered to, dispensed to, or used by a subject. The term does not include any person other than an individual (e.g.

    • Size: 68 kB
    • Last Update: 30.11.2012
  8. IIS Diabetes

    The Investigator Study Program for Diabetes aims at advancing the delivery of quality healthcare by supporting investigator original research that will enhance the understanding of disease entities and their treatment. This program is open to all academic and community-based physicians and

    • Size: 7 kB
    • Last Update: 30.11.2012
  9. Partnering

    Boehringer Ingelheim is committed to bringing innovation to farmers, veterinarians, and animals to ensure they have the best possible tools for prevention and treatment of disease.

    • Size: 9 kB
    • Last Update: 26.11.2012
  10. Experienced and Job Beginners

    Boehringer Ingelheim is interested in experienced professionals with a proven track record who are considering a challenge with one of the fastest growing pharmaceutical corporations.

    • Size: 4 kB
    • Last Update: 30.10.2012